Sen. Shippy’s bill to pause certain mRNA immunizations for children, pregnant people advances after 5–4 committee vote

The Senate Health & Welfare Committee voted to send S 1346 to the 14th Order of Business for possible amendment after a 5–4 roll call on March 4, 2026. Senator Shippy, who presented the bill, described it as "not a blanket ban but a precautionary step" proposing a two‑year moratorium on certain mRNA‑based COVID‑19 products for pregnant people and children while safety evidence is evaluated.

Supporters in the committee framed the measure as a state role in safeguarding children when products have been issued under emergency authorizations, arguing that additional time and review are warranted. Senator Shippy said the moratorium would allow alternatives and ongoing clinical trials to continue while the state reviews safety information. He also noted that, in his view, "28 jurisdictions" had declined to adopt a changed set of CDC recommendations and had maintained state‑level standards.

Opponents and cautious members raised procedural and scientific concerns. Senator Wintrow cited the bill language that "individual human gene therapy products may be exempted from the provision of the section if the Legislature determines after reviewing the safety data" and asked how that legislative review would be carried out; she said she did not see a clear mechanism in the bill for evaluating complex scientific evidence. Other senators pressed for clearer definitions of what constitutes a human gene therapy in the bill and questioned whether the Legislature had the expertise to set safety standards without relying on external expert panels.

The bill includes stated exemptions for cancer and genetic‑disorder therapies. Senators debated scope and duration: proponents said two years would permit safety data to be gathered without permanently blocking innovation; critics said the timeframe and the mechanism for reinstating products required clearer definition. The committee vote to advance the bill was: ayes — Senators Zuiderveld, Lenney, Shippy, Keyser, and Acting Senator Bjerke; nays — Senators Harris, Blaylock, Wintrow, and Chair VanOrden. The motion to send S 1346 to the 14th Order carried, and the committee did not adopt substantive amendments at the March 4 meeting.

Next steps: the bill is slated for consideration on the 14th Order for possible amendment; the committee record indicates multiple members requested narrower definitions of covered products and a clearer process for legislative review with expert input.